Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
McKinsey
Covington
US Department of Justice
Daiichi Sankyo
Farmers Insurance
Mallinckrodt
Argus Health
Chinese Patent Office

Generated: June 20, 2018

DrugPatentWatch Database Preview

VIRAMUNE Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Viramune patents expire, and when can generic versions of Viramune launch?

Viramune is a drug marketed by Boehringer Ingelheim and is included in three NDAs. There is one patent protecting this drug and one Paragraph IV challenge.

The generic ingredient in VIRAMUNE is nevirapine. There are twenty drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the nevirapine profile page.
Drug patent expirations by year for VIRAMUNE
Medical Subject Heading (MeSH) Categories for VIRAMUNE
Synonyms for VIRAMUNE
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & PRO 140 (Anti-CCR5 monoclonal antibody)
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one
11-cyclopropyl-4-methyl-5H-dipyrido[[?],[?]][1,4]diazepin-6-one
11-cyclopropyl-4-methyl-5H-dipyrido[2,3-b:3',2'-e][1,4]diazepin-6-one
11-Cyclopropyl-4-methyl-5H-dipyrido[3,2-b
11-CYCLOPROPYL-4-METHYL-5H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6(11H)-ONE
11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido-[3,2-b:2',3'-e][1,4]diazepin-6-one
11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one
11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[2,3-B:3',2'-E][1,4]DIAZEPIN-6-ONE
11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b :2',3'-e][1,4 ]diazepin-6-one
11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2 ,3 -e][1,4]diazepin-6-one
11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2', 3'-e][1,4]diazepin-6-one
11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE
11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B',3'-E][1,4]DIAZEPIN-6-ONE
129618-40-2
1vrt
2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,12,14-hexaen-10-one
2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0;{3,8}]pentadeca-1(15),3,5,7,11,13-hexaen-10-one
2-CYCLOPROPYL-7-METHYL-2,4,9,15-TETRAAZATRICYCLO[9.4.0.0(3,8)]PENTADECA-1(11),3,5,7,12,14-HEXAEN-10-ONE
2-CYCLOPROPYL-7-METHYL-2,4,9,15-TETRAAZATRICYCLO[9.4.0.0(3),?]PENTADECA-1(11),3,5,7,12,14-HEXAEN-10-ONE
2-CYCLOPROPYL-7-METHYL-2,4,9,15-TETRAAZATRICYCLO[9.4.0.0(3),?]PENTADECA-1(11),3(8),4,6,12,14-HEXAEN-10-ONE
2-CYCLOPROPYL-7-METHYL-2,4,9,15-TETRAAZATRICYCLO[9.4.0.0(3),?]PENTADECA-1(15),3(8),4,6,11,13-HEXAEN-10-ONE
2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0(3),]pentadeca-1(15),3(8),4,6,11,13-hexaen-10-one
2hny
5-Cyclopropyl-9-methyl-5,10-dihydro-4,5,6,10-tetraaza-dibenzo[a,d]cyclohepten-11-one
5H-Dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one, 5,11-dihydro-11-cyclopropyl-4-methyl-
618N402
6H-Dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl-
6H-DIPYRIDO[2,3-B:3',2'-E][1,4]DIAZEPIN-6-ONE, 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-
6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl-
6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE, 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-
99DK7FVK1H
AB0013383
AB00393001_16
AB00393001_17
AB00393001-13
AB00393001-15
AB07544
AB2000266
AC-643
AC1L1I81
AJ-08226
AK143126
AKOS005504351
ALBB-027264
AN-15635
BBL010768
BC206673
BDBM1434
BI RG 587
BI-RG 587
BI-RG-587
BI-RG-587 & CD4-IgG
BIDD:GT0326
Bio-0789
BIRG 0587
BIRG 587
BIRG-0587
BIRG-587
BIRG587
C07263
C15H14N4O
Cahill May Roberts Brand of Nevirapine
CAS-129618-40-2
CCG-100939
CHEBI:63613
CHEMBL57
CPD000048458
CS-2252
CTK8E7455
D00435
D0O2EM
DB00238
DR000811
DSSTox_CID_10787
DSSTox_GSID_31797
DSSTox_RID_78889
DTXSID7031797
F2173-0607
FT-0607215
H954
HMS2051J09
HMS2231O23
HMS3264D21
HMS3371E03
HMS3393J09
HMS3655I08
HSDB 7164
HY-10570
I02-0310
KB-64802
KS-00000KZF
KS-5019
LS-2289
MCULE-8608154492
MFCD00866928
MLS000084585
MLS000759409
MLS001055309
MLS001201730
MLS001424058
MLS006011423
MolPort-002-507-817
N0922
N11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-one & CD4-immunoadhesin
NC00189
NCGC00065890-02
NCGC00065890-03
NCGC00065890-04
NCGC00065890-05
NCGC00065890-07
NCGC00258324-01
NEV
NEVARAPINE
nevirapine
Nevirapine (anhydrous), European Pharmacopoeia (EP) Reference Standard
Nevirapine (JAN/USP/INN)
Nevirapine (Viramune)
Nevirapine [USAN:INN]
Nevirapine [USAN:USP:INN:BAN]
Nevirapine & CD4-IgG
Nevirapine & PRO 140
Nevirapine anhydrous
Nevirapine anhydrous, United States Pharmacopeia (USP) Reference Standard
Nevirapine for peak identification, European Pharmacopoeia (EP) Reference Standard
Nevirapine solution, 1.0 mg/mL in methanol, certified reference material
Nevirapine, pharmaceutical secondary standard; traceable to USP, PhEur
NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE
NQDJXKOVJZTUJA-UHFFFAOYSA-N
NSC 641530
NSC-641530
NSC-759902
NSC641530
NSC759902
NVP
Opera_ID_934
Pharmakon1600-01503842
PL004639
PL040500
PL044148
Promeco Brand of Nevirapine
R3924
RL01415
RT-014690
S1742
SAM001246551
SC-17266
SCHEMBL3318
SMR000048458
ST24038235
STK580320
Tox21 110982
Tox21_110982
Tox21_110982_1
Tox21_200770
UNII-99DK7FVK1H
Viramune (TN)
Viramune IR
Viramune XR
Viramune, BI-RG 587, Nevirapine
Viramune;BI-RG 587
Viramune(TM)
Z1695906730
ZB000592
ZINC4778

US Patents and Regulatory Information for VIRAMUNE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim VIRAMUNE nevirapine SUSPENSION;ORAL 020933-001 Sep 11, 1998 AA RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Boehringer Ingelheim VIRAMUNE XR nevirapine TABLET, EXTENDED RELEASE;ORAL 201152-001 Mar 25, 2011 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Boehringer Ingelheim VIRAMUNE nevirapine TABLET;ORAL 020636-001 Jun 21, 1996 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Boehringer Ingelheim VIRAMUNE XR nevirapine TABLET, EXTENDED RELEASE;ORAL 201152-002 Nov 8, 2012 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for VIRAMUNE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim VIRAMUNE nevirapine SUSPENSION;ORAL 020933-001 Sep 11, 1998 ➤ Try a Free Trial ➤ Try a Free Trial
Boehringer Ingelheim VIRAMUNE nevirapine TABLET;ORAL 020636-001 Jun 21, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for VIRAMUNE
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Extended-release Tablets 400 mg ➤ Subscribe 2013-06-21

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Accenture
Johnson and Johnson
Harvard Business School
Chubb
Dow
Citi
Queensland Health
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.